BCRX Biocryst Pharmaceuticals Inc stock chart & analysis
Conviction 23HealthcareScan · Fri, Nov 6, 2026Biocryst Pharmaceuticals Inc (BCRX) closed at $7.69 (+0.79%) on Nov 6, 2026. Its latest daily candle is a hanging man. Price is below its 50-day and below its 200-day moving average. RSI(14) 41, RS Rating 42, -31.6% from its 52-week high, -1.5% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Financials as of Wed, Sep 30, 2026 · quarterly.
BCRX technical analysis
Trend
BCRX is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 9.3% below the 50-day ($8.46) and 12.5% below the 200-day ($8.78). The 50-day crossed below the 200-day (a death cross) 8 sessions ago. ADX(14) at 17 points to a weak trend — more range than direction. It meets 2 of 8 trend-template criteria.
Momentum
RSI(14) is 41, in the bearish half of its range. MACD crossed below its signal line on the latest session. A bullish RSI divergence is in place. A bullish MACD divergence is in place. Its RS Rating of 42 puts its weighted 12-month performance ahead of about 42% of the US market.
Volume and volatility
Volume on the latest session ran 0.7× its 20-day average. It trades about $47.2M a day on average. ATR(14) is $0.3824, 5.0% of price — its typical daily range. On-balance volume is trending down.
Key levels
The 52-week range is $6.23 to $11.22; price is 31.6% below the high and 23.3% above the low. The VWAP anchored at the 52-week high is $8.74, above price.
Performance
BCRX returned -9.3% (1 week), -7.4% (1 month), -21.9% (3 months), -10.9% (6 months), +7.1% (1 year), -1.5% (year to date).
About Biocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Biological Products, (No Diagnostic Substances) · Listed 1994 · 435 employees
Congress activity
Disclosed STOCK Act trades in BCRX · 2 recent
Insider activity
SEC Form 4 transactions in BCRX
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Frank Steven Director · Common Stock · 2026-08-31 | Grant | 1.29K | $12K | 2026-08-31 | 2026-09-02 |
McKee Amy E Director · Common Stock · 2026-08-31 | Grant | 644 | $6K | 2026-08-31 | 2026-09-02 |
MILANO VINCENT Director · Common Stock · 2026-08-31 | Grant | 1.16K | $11K | 2026-08-31 | 2026-09-02 |
Milne Jill C. Director · Common Stock · 2026-08-31 | Grant | 1.29K | $12K | 2026-08-31 | 2026-09-02 |
Stonehouse Jon P Director · Common Stock · 2026-08-31 | Grant | 644 | $6K | 2026-08-31 | 2026-09-02 |
Frank Steven Director · Common Stock · 2026-05-29 | Grant | 1.26K | $11K | 2026-05-29 | 2026-06-02 |
Stonehouse Jon P Director · Common Stock · 2026-05-29 | Grant | 631 | $6K | 2026-05-29 | 2026-06-02 |
Stonehouse Jon P Director · Common Stock · 2026-05-29 | Other | — | — | 2026-05-29 | 2026-06-02 |
MILANO VINCENT Director · Common Stock · 2026-05-29 | Grant | 1.12K | $10K | 2026-05-29 | 2026-06-02 |
McKee Amy E Director · Common Stock · 2026-05-29 | Grant | 631 | $6K | 2026-05-29 | 2026-06-02 |
SEC filings
EDGAR filings in BCRX · 9 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.